Teva announces launch of its generic version of canasa® (mesalamine) suppositories to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the united states

Tel aviv & parsippany, n.j.--(business wire)--teva pharmaceuticals usa, inc., a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the launch of its 1000 mg strength generic version of casana®1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the u.s. ulcerative colitis (uc) results in inflammation or swelling of the rectum (the area between the colon and the anus). this inflammation
TEVA Ratings Summary
TEVA Quant Ranking